CD274 and neoplasm: The combination treatment group also showed increased proportion of PD-L1 on tumor cells compared with the control and the gemcitabine group (13.0% ± 1.26% vs.7.53% ± 1.29%,P= 0.0290;13.0% ± 1.26% vs.7.10% ± 2.06%,P= 0.0178, Figure 5B).